G. Brusselle (Ghent, Belgium), P. Paggiaro (Pisa, Italy)
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
G. Brusselle, C. S. Lee, S. Gurdain, S. Vancayzeele, P. Lecomte, C. Hermans, K. MacDonald, M. Song, I. Abraham (Ghent, Vilvoorde, Belgium; Earlysville, Philadelphia, Tucson, United States Of America)
|   |
Effects of a monitoring programme on difficult asthmatics
F. Novelli, F. L. Dente, L. Melosini, M. Latorre, E. Bacci, A. Di Franco, M. De Santis, P. Paggiaro (Pisa, Italy)
| |
Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma
A. Singapuri, P. Haldar, P. Bradding, R. Green, A. Wardlaw, C. E. Brightling, I. Pavord (Leicester, United Kingdom)
| |
Practical utility of portable exhaled nitric oxide (eNO) readings to aid in asthma management plans – a district general hospital (DGH) experience
J. Wall, S. Dermott, I. Aziz (Wigan, United Kingdom)
| |
Effect of omega-3 and phosphoethanolamine in patients with asthma
D. B. Piai, R. Quagliato Júnior, A. Barbeiro, G. Yonezawa, G. O. Chierice (Campinas, São Carlos, Brazil)
| |
Effects of a 12-month course with omalizumab on basement membrane thickness in severe persistent atopic asthma
R. W. Dal Negro, S. Tognella, F. Trevisan, M. Visconti, C. Micheletto (Bussolengo, Italy)
| |
Impact on steroid dosing after introducing sputum eosinophils count into a severe asthma clinic
G. Tavernier, O. Francies, R. Niven (Manchester, United Kingdom)
| |
Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age
S. Korn, C. Schumann, C. Kropf, K. M. Stoiber, A. Thielen, C. Taube, O. Kornmann, R. Buhl (Mainz, Ulm, Nürnberg, Germany)
| |
Review of anti-IgE subcutaneous injection for adult asthmatic patients treatment in Ramathibodi hospital Bangkok Thailand
T. Kawamatawong, T. Limsuwan (Bangkok, Thailand)
| |
Effects of N-acetylcysteine on asthma exacerbation
M. Aliyali, A. Pourhassanamiri, A. Sharifpor, F. Zali (Sari, Babol, Islamic Republic Of Iran)
| |
Uncontrolled and partly controlled asthma due to non-adherence to the treatment: specific drug and non-drug factors
J. Minov, J. Karadzinska-Bislimovska, K. Vasilevska, S. Risteska-Kuc, S. Stoleski (Skopje, Fyrom)
| |
Evaluation of difficult asthma – a single centre experience
C. C. Cocian, K. Serban, C. L. Toma, C. E. Tudose, M. A. Bogdan, D. Bumbacea (Bucharest, Romania)
| |
Mometasone furoate/formoterol (mf/f) combination treatment in patients with moderate-to-severe asthma: findings from a 1-yr safety trial
J. Máspero, I. Chérrez, H. Nolte (Buenos Aires, Argentina; Guayaquil, Ecuador; Kenilworth, United States Of America)
| |
Omalizumab in severe uncontrolled asthma: two and a half year clinical experience
M. D. C. Vennera, R. Mora, A. Valero, J. Bartra, R. Muñoz, C. Picado (Barcelona, Spain)
| |
Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
S. Salvi, K. Bhosle, B. Brashier, S. Limaye, S. Mandrekar, S. Gaikwad, S. Ghorpade (Pune, India)
| |
Challenges in classification of asthma severity from prescription data: a pilot study
J. R. Davidsen, J. Soendergaard, J. Hallas, H. C. Siersted, M. Andersen (Odense, Denmark)
| |
The efficacy of omalizumab in severe in asthma after treatment withdrawal
M. Kodric, M. Biolo, R. Della Porta, R. Cifaldi, P. Geri, C. Torregiani, S. Samarro, C. Longo, M. Confalonieri (Trieste, Italy)
| |
Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma
T. Pertseva, K. Gashynova, O. Gurzhiy, K. Kaiser (Dnipropetrovsk, Ukraine; Muttenz, Switzerland)
| |
Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients
S. Weinstein, M. White, J. Corren, H. Nolte (Huntington Beach, Wheaton, Los Angeles, Kenilworth, United States Of America)
| |
The association between fat mass, disease control and airway inflammation in refractory asthma
A. Singapuri, M. Bafadhel, S. Pickering, B. Hargadon, W. Monteiro, S. Gupta, A. Wardlaw, I. Pavord, C. E. Brightling (Leicester, United Kingdom)
| |